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Phosphorylation of nuclear Tau 
is modulated by distinct cellular 
pathways
Giorgio Ulrich1, Agnese Salvadè1, Paul Boersema2, Tito Calì  3, Chiara Foglieni1, 
Martina Sola1, Paola Picotti2, Stéphanie Papin1 & Paolo Paganetti  1
Post-translational protein modification controls the function of Tau as a scaffold protein linking a 
variety of molecular partners. This is most studied in the context of microtubules, where Tau regulates 
their stability as well as the distribution of cellular components to defined compartments. However, 
Tau is also located in the cell nucleus; and is found to protect DNA. Quantitative assessment of Tau 
modification in the nucleus when compared to the cytosol may elucidate how subcellular distribution 
and function of Tau is regulated. We undertook an unbiased approach by combing bimolecular 
fluorescent complementation and mass spectrometry in order to show that Tau phosphorylation 
at specific residues is increased in the nucleus of proliferating pluripotent neuronal C17.2 and 
neuroblastoma SY5Y cells. These findings were validated with the use of nuclear targeted Tau and 
subcellular fractionation, in particular for the phosphorylation at T181, T212 and S404. We also report that 
the DNA damaging drug Etoposide increases the translocation of Tau to the nucleus whilst reducing 
its phosphorylation. We propose that overt phosphorylation of Tau, a hallmark of neurodegenerative 
disorders defined as tauopathies, may negatively regulate the function of nuclear Tau in protecting 
against DNA damage.
Proteinopathies represent a large spectrum of human disorders caused by proteins with a cytotoxic gain of func-
tion or the failure to perform a normal activity, both due to abnormal conformation and modification1. In their 
pathogenic forms, these proteins hold the predisposition to self-assemble into toxic soluble oligomers or insoluble 
aggregates. Given that cellular protein clearance is less efficient for multimeric or aggregated protein assemblies, a 
gradual accumulation and the formation of large deposits such as those typical for progressive neurodegenerative 
disorders may occur2. This is further accelerated by aging, which correlates with proteostasis defects, mostly due 
to a decline in protein clearance3. Other liabilities are increased protein production, abnormal post-translational 
modification, or changes in the amino acid sequence of the protein in genetic variants causing hereditary disease 
forms4. The aging brain may be concerned by the co-existence of distinct proteinopathies such as those involv-
ing Tau in neurofibrillar tangles and β-amyloid plaques in Alzheimer’s disease, or α-synuclein in Lewi bodies of 
Parkinson’s disease5,6. Then again, distinct proteinopathies may cause clinically similar disorders as it is the case 
for the deposition of aberrant forms of Tau, FUS or TDP-43 in the ALS/FTD disease spectrum7. Tauopathies, both 
in sporadic and familial forms of frontotemporal dementia with parkinsonism-17 caused by mutations in the Tau 
gene (MAPT), are characterized by Tau assembled in highly ordered paired helical filaments within neuronal 
cells8,9.
Tau was originally isolated as a microtubule-associated protein10. Its primary structure covers domains 
with distinct characteristics typical of a scaffold protein: an amino-terminal projection sequence followed by 
a proline-rich sequence domain, a microtubule-binding region and a carboxy-terminal tail. In its unbound 
state, Tau is described as highly soluble, heath-stable, unfolded protein. Tau binding to microtubules leads to a 
conformational switch with the negatively charged projection domain dissociating from the positively charged 
microtubule-binding domain. Tau links microtubules to other binding partner such as motor complexes or cel-
lular membranes11, a process that is regulated by post-translational modifications9,12. Tau is post-translationally 
modified by proteolysis, acetylation, methylation, glycosylation and phosphorylation. This latter is the prevalent 
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modification with more than eighty potential sites at serines, threonines and tyrosines. About twenty sites contrib-
ute to the normal function of Tau, but increased phosphorylation at these or at additional sites occurs during early 
development and is present in pathological lesions13. Phosphorylation within or outside the microtubule domain 
affects Tau association to microtubules. This may disturb microtubule-mediated axonal transport or increase free 
Tau, the probability of fibril formation14 or its secretion as a critical event for cell-to-cell spreading of Tau lesions 
in the brain15,16. Microtubule-dissociated Tau may also locate to other cellular compartments11,17,18. Toxic insults 
induce abnormal Tau distribution, as it is the case for β-amyloid-mediated re-location of Tau from the axonal to 
the somatodendritic compartment of neurons19. Distinct cellular locations of Tau may be associated to different 
post-translational modifications9,12,20 and different post-translational modifications of Tau may be associated to 
different functions, e.g. at the neuronal synapse21,22. Intriguingly, Tau is also found in the nucleus in vitro23–27  
and in vivo28. Tau interacts with RNA and DNA29–32 and appears to protect DNA from denaturation and radi-
cals33–36. Binding of DNA by Tau is linked to its dephosphorylated form37.
In our study, we revisited the hypothesis that nuclear Tau is characterized by a distinct post-translational mod-
ification. Using a set of parallel approaches to characterize Tau modification in the nucleus, we found increased 
phosphorylation at distinct sites for nuclear localized Tau and identified pharmacological modulators that differ-
entially affect the subcellular location and modification of Tau.
Results
Cellular distribution of Tau by bimolecular fluorescent complementation. Bimolecular fluores-
cence complementation (biFC) represents a relatively simple technology to reveal subcellular protein location38. 
We adapted biFC to investigate the presence of Tau in specific sublocations within cultured cells. Here, we gen-
erated GFP1–10 sensors targeted to the nucleus, to the lumen of the endoplasmic reticulum (ER) or to the mito-
chondrial outer membrane (OMM). For the nuclear targeting sequence fused at the amino-terminus of GFP1–10 
(nucGFP1–10), we took advantage of a well-described artificial targeting peptide carrying three times a nuclear 
targeting sequence derived from the SV40 large T antigen39. For the erGFP1–10 sensor, we fused the signal peptide 
of human calreticulin at the amino-terminus of the sensor and added the ER retention signal KDEL at its car-
boxy-terminus (Fig. 1a). The ommGFP1–10 sensor was generated as described18,40. The correct cellular distribution 
of the sensors was then assessed by immune fluorescent staining of transiently transfected mouse pluripotent 
neuronal C17.2 cells using an antibody against GFP. Cells were counterstained for calnexin located in the ER 
and the nuclear envelop and with the dye DAPI binding to the nuclear DNA. This procedure revealed the ubiq-
uitous (i.e. cytosolic and nuclear) distribution of the untargeted GFP1–10 sensor, the nuclear localization of the 
nucGFP1–10 sensor that overlapped with the DAPI staining, and the co-localization of the ER-marker calnexin 
with the erGFP1–10 sensor but not with the ommGFP1–10 sensor associated to mitochondria40 (Fig. 1a). The spec-
ificity of α-GFP staining was highlighted by the absence of signal in the surrounding untransfected cells, which 
were positive only for calnexin and DAPI (Fig. 1a). A subcellular distribution consistent to that observed in C17.2 
cells was obtained in human kidney HEK293 cells and in human SH-SY5Y neuroblastoma cells (Supplementary 
Fig. 1).
In order to reconstitute GFP fluorescence, we then co-transfected C17.2 cells with the longest – 441 
amino-acid long – isoform of human Tau fused at the amino-terminus with the eleventh β-strand of GFP (S11). 
S11 complements the GFP1–10 sensor for reconstituting a biofluorescent GFP. Co-location of S11-Tau and GFP1–10, 
resulted in strong cytosolic reconstituted GFP-fluorescence (biFC) (Fig. 1b). Here, cells were counter-stained with 
a human-specific Tau antibody, which revealed accurate co-localization of biFC with the expected cellular distri-
bution of Tau along microtubules. The use of the nucGFP1–10 sensor revealed the presence of Tau within the cell 
nucleus, whereas ommGFP1–10 demonstrated mitochondria-associated Tau. Thus, although the main pool of Tau 
was again detected in the cytosol by the α-Tau antibody, the two targeted sensors visualized minor pools of Tau 
within the nucleus or bound to mitochondria (Fig. 1b). Microtubule-associated Tau was better visualized with a 
β-tubulin antibody when the cells were fixed in ice-cold methanol38, on the other hand methanol fixation was less 
suited to reveal the GFP biofluorescent signal and protein localization within the nucleus. No biFC was obtained 
with the erGFP1–10 sensor (Fig. 1b) and for that matter also with a GFP1–10 sensor targeted to the mitochon-
drial matrix (Supplementary Fig. 2)18 indicating the absence of detectable Tau protein levels within the secretory 
pathway or mitochondria. In order to show the functionality of the erGFP1–10 sensor, we generated a construct 
encoding for a Tau carrying at its amino-terminus the signal peptide of influenza hemagglutinin followed by 
a consensus sequence for amino-glycosylation, whereas the S11-peptide was added at the carboxy-terminus 
(erTau-S11). Tau targeted to the lumen of the ER complemented the erGFP1–10 sensor and generated a biFC signal 
(Fig. 1b) that co-localized with the ER-maker calnexin. Additional evidence for the presence of erTau-S11 in the 
secretory pathway was its significantly slower migration on SDS PAGE due to plausible glycosylation (see below 
Fig. 2b, compare lanes 7 and 4) and robust secretion.
The aim of this study was to assess whether distinct subcellular location of Tau may affect its post-translational 
modification. So, the next step was to first examine whether C17.2 cells actively modified Tau. For this, we ana-
lysed Tau on SDS polyacrylamide gel electrophoresis followed by western blot with the Tau13 monoclonal anti-
body (Fig. 2a, lane 4; Supplementary Fig. 3). This analysis revealed that human Tau in C17.2 cells displayed a 
heterogeneous apparent molecular weight, as known for phosphorylated Tau. Consistent with this interpretation, 
the majority of the Tau forms on the western blot had a larger apparent molecular mass than that of the unmodi-
fied recombinant Tau441 expressed in bacteria (Fig. 2a, lane 2; Supplementary Fig. 3). Treatment of cell lysates with 
λ-phosphatase reduced heterogeneity and apparent molecular mass of Tau expressed by C17.2 cells, comparably 
to that of recombinant Tau (Fig. 2a, lane 3; Supplementary Fig. 3). Similar migration pattern and sensitivity to 
λ-phosphatase was observed also for endogenous human Tau and for overexpressed Tau441 in human SH-SY5Y 
cells, for overexpressed Tau441 in human HEK293 cells and for S11-Tau in mouse C17.2 cells (Supplementary 
Fig. 4). Moreover, Tau protein forced into the nucleus by the same nuclear import signal used for the sensor 
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(nucTau, Fig. 2b) showed multiple complex post-translational modification and sensitivity to λ-phosphatase 
(Fig. 2a, lanes 6 and 7; Supplementary Fig. 3). Specificity of the human-specific mouse monoclonal Tau13 anti-
body was emphasized by the absence of immune positive signals in mock-transfected mouse C17.2 cells, despite 
the presence of endogenous mouse Tau (Fig. 2a, lane 1; Supplementary Fig. 3). Reduced GAPDH signal, used 
as loading control in this experiment, indicated partial unspecific protein degradation in the cell lysates treated 
with λ-phosphatase when compared to the untreated control (Fig. 2a, compare lanes 3 and 4 or lanes 6 and 7; 
Figure 1. Targeted GFP1–10 sensors reveal subcellular pools of Tau. (a) The subcellular distribution of the 
indicated GFP1–10 sensors in transiently transfected mouse C17.2 cells is shown by confocal microscopy upon 
immune staining of PFA-fixed cells with an anti-GFP antibody (upper row, in red). The cells are counter-stained 
with the ER-marker calnexin (middle row, in cyan) and the nuclear stain DAPI (shown in the merged images, 
bottom row, in blue). (b) The GFP1–10 sensors were then co-transfected with S11-Tau, which reveals by biFC 
biofluorescence (upper row, in green) microtubule-associated Tau with GFP1–10, nuclear Tau with nucGFP1–10, 
and mitochondria-associated Tau with ommGFP1–10. No biFC is obtained with the erGFP1–10 sensor, unless Tau 
is targeted to the ER lumen (erTau-S11, column on the far right). The cells are counter-stained for total human 
Tau with the Tau13 antibody (middle row, in red) and DAPI (merged images, bottom row, in blue).
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Supplementary Fig. 3), which may explain the presence of a putative proteolytic fragment of Tau migrating 
slightly faster than the main Tau band in the λ-phosphatase-treated lysates (Fig. 2a, lane 3; Supplementary Fig. 3).
Mass Spectrometry reveals subcellular-specific Tau phosphorylation. Having established the pres-
ence of Tau within the nucleus of C17.2 cells (Fig. 1b) and its post-translational modification by phosphorylation 
(Fig. 2a), next we optimized conditions for the isolation of S11-Tau using the GFP1–10 sensors as immune isola-
tion baits, in order to characterize Tau modification depending on its cellular distribution38. First, we prepared 
detergent-free extract obtained from C17.2 cells co-transfected with S11-Tau and GFP1–10 and demonstrated the 
presence of the two biFC partners by western blot (Fig. 3a, lane 5). Immune isolation of the GFP-containing biFC 
complex was performed by single-step affinity purification with anti-GFP VHH antibody coupled to magnetic 
agarose beads (GFP-Trap). This procedure, led to efficient co-purification of S11-Tau from extract obtained from 
cells co-transfected with S11-Tau and GFP1–10 (Fig. 3a, lane 10). In order to evaluate the specificity of the immune 
isolation procedure, the negative controls included cell extracts obtained from mock transfected cells (Fig. 3a, 
lane 1), cells transfected with either one of the two proteins without the respective biFC partner (Fig. 3a, lanes 
2, 3, 7, 8), or replacing the GFP1–10 sensor with intact GFP (Fig. 3a, lanes 4 and 9). Tau immune reactivity in 
the GFP-bound fractions was very faint, i.e. at unspecific background levels, in the samples obtained from cells 
lacking GFP1–10 or co-expressing intact GFP instead of GFP1–10. Moreover, mixing cell extracts obtained from 
cells expressing separately S11-Tau or GFP1–10 before the immune isolation did not result in co-isolation of Tau 
(Fig. 3a, lanes 6 and 11). This showed lack of post-extraction GFP reconstitution, which reduced the liability of 
co-isolating Tau protein assembled post-extraction with the GFP1–10 sensor when the two binding partners did 
not co-localized in intact cells. β-actin immune blotting was used as loading control for the unprocessed cell 
extracts, and its absence in the GFP-immune isolates was a further evidence of the specificity of the enrichment 
procedure. Furthermore, based on the results obtained with standard immune precipitation with the αGFP rab-
bit polyclonal ab290 coupled to protein G-agarose beads, it should be noted that GFP-Trap inefficiently isolated 
unreconstituted GFP1–10. Based on these data, we predicted isolation of subcellular Tau pools from cells express-
ing different targeted GFP1–10 sensors by GFP-Trap. This procedure would consent the identification of subcellular 
location-specific post-translational modifications of Tau, which we did by LC-MS/MS analysis.
We then generated scaled-up extracts from C17.2 cells transfected with plasmids encoding S11-Tau and 
the untargeted GFP1–10 or the nucGFP1–10 sensors (Fig. 3b, lanes 2 and 3) and isolated the biFC complex with 
GFP-Trap (Fig. 3b, lanes 6 and 7). The specificity of the affinity purification for reconstituted GFP formed before 
cell extraction was confirmed with the erGFP1–10 sensor. Consistent with the biFC data by microscopy (Fig. 1b), 
Tau-affinity purification by means of erGFP1–10 sensor occurred from cells expressing ER-targeted erTau-S11 but 
not when expressing S11-Tau (Fig. 3b, lanes 4, 5, 8, 9). The same procedure was also applied to isolate ommG-
FP1–10-bound Tau (Supplementary Fig. 5). Next, GFP-affinity isolated Tau was digested with Lys-C/trypsin and 
the resulting peptides were analysed by LC-MS/MS. Sequence coverage resulting from this analysis reached 81% 
of the Tau polypeptide (Fig. 4). Search for post-translationally modified human Tau-derived peptides revealed 
multiple phospho-threonine and -serine residues (Fig. 4 and Table 1). No other classes of post-translational mod-
ifications were detected among those searched, i.e. lysine methylation, acetylation, ubiquitination and nitration. 
Out of the thirteen phosphopeptides detected, two exhibited double-phosphorylation. The first included two 
Figure 2. Tau and nuclear targeted Tau are phosphorylated in C17.2 cells. (a) Cell extracts (10 µg total protein) 
obtained from C17.2 cells transiently transfected with Tau (Tau441) or nuclear targeted Tau (nucTau) are 
analysed by western blot with the human-specific Tau13 antibody in the absence or presence of λ-phosphatase 
treatment (λ-phosph). Bacterial recombinant Tau was mixed with a mock transfected cell lysate (recTau441). 
GAPDH served as a loading control. (b) Confocal microscopy images of C17.2 cells demonstrate nuclear 
targeting of nucTau (Tau13 staining, in red). Cells are counterstained for microtubules (α-tubulin, in cyan) and 
the nucleus (DAPI, in blue in the merged image).
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threonines (T175 and T181; numbering according to the Tau441 isoform), and the other a threonine and a serine 
(T231 and S235). For all phosphosites detected, the corresponding unmodified residue was also identified, indicat-
ing that the sites are partly phosphorylated in C17.2 cells under normal culturing conditions. All samples were 
analysed twice and we calculated mean peptide intensity from the two measurements, each normalized for the 
total intensities for all human Tau-derived peptides. We then compared the relative intensities of the phospho-Tau 
peptides isolated by means of the GFP1–10, nucGFP1–10 or the ommGFP1–10 sensors (Table 1). Significantly 
Figure 3. Immune isolation of Tau by mean of the GFP1–10 sensors. (a) Cell lysates from C17.2 cells transfected 
as indicated are analysed by western blot before (cell lysates) or after immune isolation on anti-GFP magnetic 
beads (GFP-Trap isolates). This shows specific isolation of S11-Tau when co-transfected with GFP1–10, but not in 
the negative controls, including post-lysis mixing of lysates obtained from cells transfected with either S11-Tau 
or GFP1–10 (lanes labelled with “mix”). β-actin is the loading control for the cell lysates, whereas the presence of 
the sensor is verified with an anti-GFP antibody. (b) Cell lysates and GFP-immune isolates obtained from C17.2 
cells transiently transfected with S11-Tau and the indicated sensors are analysed by western blot as described for 
(a). Molecular weight markers are given on the left of the blots, full blots are shown scanned by dual infrared 
imaging.
Figure 4. LC-MS/MS reveals Tau phosphorylation. Primary sequence of human Tau441 with highlighted 
sequence coverage (81%; letters in black) and phosphorylation sites (letters in red) revealed by LC-MS/MS. The 
microtubule binding domain of Tau is underlined.
www.nature.com/scientificreports/
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increased phosphorylation of peptides embedding T181, one of the three S198/199/202 (the exact position was not 
resolved), T212 and the double-phosphorylation at T231/S235 was detected in samples isolated with the nucGFP1–10 
sensor when compared to GFP1–10 or ommGFP1–10. A significant increase in the abundance of the phosphopep-
tide embedding S404 was found for nucGFP1–10-Tau when compared to GFP1–10-Tau, but not for ommGFP1–10-Tau, 
possibly suggesting a differential Tau modification at mitochondria when compared to the cytosol as recently 
discussed18, and also supported by increased pS356 and reduced pT231/pS235 for ommGFP1–10-Tau when compared 
to GFP1–10-Tau. For all other phosphosites no differences between the sensors were found. In order to consolidate 
these results, in a second analysis, we probed biological pentaplicates for the GFP1–10 and nucGFP1–10 sensors. The 
overall recovery of peptides in this analysis was lower than the first one, with seven distinct phosphosites detected 
(Table 2). Here, nucGFP1–10-bound Tau was significantly more phosphorylated at T181 and T231, whereas phos-
phorylation at the other sites was not significantly different. Overall, the mass spectrometric analysis revealed 
an increased phosphorylation for Tau isolated with the nucGFP1–10 sensor compared to that of the ubiquitously 
distributed GFP1–10 or ommGFP1–10, at least at three threonine and two serine residues out of the thirteen phos-
phosites measured. These findings were unforeseen considering previous work performed by immune staining 
with the dephosphorylated specific Tau1 antibody37. Therefore, we challenged our data by undertaking two inde-
pendent approaches based on western blot analysis with commercial phospho-specific antibodies.
Nuclear targeting of Tau modifies its phosphorylation. For the first approach, C17.2 cells were trans-
fected with untagged human Tau441 or nuclear targeted nucTau (Fig. 2b). One day later, total cell lysates were analysed 
by western blot, whereby cell lysates were loaded in a way to obtain similar amounts of Tau (Fig. 5a, Supplementary 
Fig. 6). Relative phosphorylation, after normalization for Tau measured with the Tau13 pan-antibody, was deter-
mined for biological triplicates, and calculated as ratio of the value for nucTau over that of wild-type Tau (Fig. 5b). 
Phosphorylation was increased for nucTau at the three sites examined, i.e. T181 by 3.8 ± 0.4 fold the value of wild-type 
Ctrl: GFP1–10 nucGFP1–10 ommGFP1–10 nuc vs ctrl nuc vs omm omm vs ctrl
n = 3 SD n = 2 SD n = 3 SD p ratio p ratio p ratio
pT181 2.49% 0.22% 3.11% 0.25% 2.13% 0.34% 0.004 1.2 6 × 10−6 1.5 ns 0.9
pT175 + pT181 0.05% 0.03% 0.04% 0.02% 0.01% 0.01% ns 0.8 ns 3.3 ns 0.2
pS198/199/202 2.55% 0.10% 3.42% 0.37% 2.19% 0.09% 5 × 10−5 1.3 <10−6 1.6 ns 0.9
pT212 0.71% 0.11% 1.31% 0.08% 0.41% 0.07% 0.006 1.9 3 × 10−5 3.2 ns 0.6
pS214 0.25% 0.03% 0.17% 0.01% 0.15% 0.06% ns 0.7 ns 1.2 ns 0.6
pT217 0.10% 0.02% 0.08% 0.05% 0.07% 0.01% ns 0.8 ns 1.2 ns 0.7
pT231 0.65% 0.08% 0.75% 0.11% 0.63% 0.15% ns 1.2 ns 1.2 ns 1.0
pT231 + pS235 3.16% 0.48% 3.65% 0.81% 1.91% 0.37% 0.032 1.2 <10−6 1.9 <10−6 0.6
pS262 0.01% 0.01% 0.02% 0.01% 0.04% 0.03% ns 2.5 ns 0.5 ns 5.5
pS356 0.16% 0.02% 0.17% 0.13% 0.57% 0.55% ns 1.1 ns 0.3 0.047 3.5
pS396 0.02% 0.01% 0.01% 0.01% 0.01% 0.01% ns 0.7 ns 1.0 ns 0.7
pS404 0.28% 0.02% 0.78% 0.19% 0.53% 0.02% 0.027 2.7 ns 1.5 ns 1.9
pS416 0.19% 0.04% 0.11% 0.03% 0.07% 0.06% ns 0.6 ns 1.5 ns 0.4
Table 1. First LC-MS/MS mass spectrometric analysis of Tau phosphorylation isolated with different GFP1–10 
sensors. Tryptic peptides obtained from the indicated GFP1–10-Tau immune isolates were analysed twice and 
the mean peptide intensities, each normalized for the total abundance of all Tau peptides, are given as the 
relative mean percent for each phosphosite (human Tau441 numbering). 2way ANOVA and Tukey’s multiple 
comparison test (alpha 0.05).
GFP1–10 nucGFP1–10
p ratiomean SD mean SD
pT181 0.28% 0.31% 0.91% 0.32% 0.012 3.3
pS198/199/202 2.16% 0.80% 2.33% 0.39% ns 1.1
pT212 0.04% 0.03% 0.30% 0.24% ns 7.6
pT231 0.50% 0.26% 1.16% 0.43% 0.009 2.3
pT231 + pS235 0.21% 0.19% 0.63% 0.46% ns 3.1
pS262 0.05% 0.03% 0.11% 0.07% ns 2.3
pS404 2.71% 1.07% 2.89% 0.55% ns 1.1
pS416 0.14% 0.13% 0.04% 0.05% ns 0.3
Table 2. Second LC-MS/MS mass spectrometric analysis of Tau phosphorylation isolated with GFP1–10 or 
nucGFP1–10. Tryptic peptide intensities, each normalized for the total abundance of all Tau peptides, are given 
as relative percent for each phosphosite (human Tau441 numbering). 2way ANOVA and Bonferroni’s multiple 
comparison test (n = 5, alpha 0.05).
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Tau (p 1 × 10−9, 2way ANOVA, alpha 0.05), T212 by 4.0 ± 0.2 fold (p 6 × 10−10) and S404 by 2.4 ± 0.2 fold (p 9 × 10−5). 
Notably, nucTau detection was also increased for the Tau1 antibody with 2.6 ± 0.2 fold (p 1 × 10−5), specific for 
non-phosphorylated Ser195/198/199/20241. All phosphorylation dependent sites were also increased for nucTau in tran-
siently transfected human SH-SY5Y cells (Fig. 5c, Supplementary Fig. 7): T181 by 1.8 ± 0.1 (p 4 × 10−7), T212 by 
4.0 ± 0.4 (p 1 × 10−15), S404 by 1.5 ± 0.1 (p 0.004) and Tau1 by 1.8 ± 0.3 (p 8 × 10−7).
Analysis of wild-type Tau phosphorylation in a nuclear fraction. For the second approach, we took 
advantage of the availability in the laboratory of a mouse C17.2 cell line with tetracycline-inducible expression 
of human Tau441 in order to isolate enriched cytosolic and nuclear fractions by a differential centrifugation pro-
cedure. Purity of the fractions was assessed by immune detection with the cytosolic GAPDH marker and the 
nuclear H3 marker histone 3 (Fig. 6a, Supplementary Fig. 8). Quantification of the signals obtained from bio-
logical triplicates demonstrated for the nuclear fraction a presence of GAPDH reaching 2.0 ± 1.6% for GAPDH, 
99.6 ± 5.4% for H3 and 17.3 ± 2.5% for Tau (Fig. 6b). In order to analyse same amounts of Tau for both fractions, 
the nuclear samples were concentrated by 3-chloroacetic acid (TCA) precipitation before detecting phosphoryl-
ated Tau by western blot (Fig. 6c, Supplementary Fig. 9). Again, nuclear Tau displayed increased phosphorylation 
at T181 by 2.2 ± 0.2 fold the value of normal Tau (p 3 × 10−5, 2way ANOVA, alpha 0.05.), S404 (2.4 ± 0.1 fold; 
p 0.043) and decreased phosphorylation at the Tau1 epitope (1.6 ± 0.2 fold; p 0.0001) (Fig. 6d). Also T212 was 
found more phosphorylated in the nuclear fraction when compared to the cytosolic fraction, but this did not 
reach significance (3.2 ± 2.1%; p 0.9), possibly because the detection of pT212 in both fractions was only slightly 
above background determined with samples obtained from untransfected C17.2 cells, resulting in high variation 
between replicates.
Figure 5. Nuclear targeting of Tau modifies its phosphorylation. (a) Cell lysates obtained from C17.2 cells 
transiently transfected with Tau or nucTau are analysed by western blot with pan-Tau antibody Tau13 or 
antibodies against the indicated phosphosites or dephosphorylated Ser195/198/199/202 (Tau1). Molecular weight 
markers are shown on the left. (b and c) Quantification of Tau and nucTau and their modifications in C17.2 
(n = 3) or SH-SY5Y (n = 5) cells. Values are mean ± SD. 2way ANOVA and Bonferroni’s multiple comparison 
test, **p < 0.01, ***p < 0.001.
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DNA damage modifies subcellular location and modification of Tau. Having established that 
Tau phosphorylation depends on its subcellular location, we analysed whether compounds expected to affect 
cellular Tau distribution may influence Tau modification. We focused our attention on treatments known to 
cause a nuclear Tau translocation following DNA damage, or to interfere with the Tau-microtubule interaction. 
Microscopic immune-fluorescent analysis of C17.2 cells with induced human Tau expression confirmed that 
treatment with the topoisomerase II inhibitor Etoposide induced activation of the DNA damage response, visu-
alized with phospho-specific antibodies against γH2A-X (Fig. 7a) or against four nuclear phosphorylated kinases 
(Fig. 7b). Quantification of the fluorescent signal by confocal microscopy in the DAPI-stained nuclei demon-
strated that activation of the early DNA damage response kinases in the presence of Etoposide, when compared 
to the untreated controls, reached 173 ± 3% for ATM (mean ± sem, n = 218 nuclei, p 10−15, 2-tailed unpaired 
Mann-Whitney test), 165 ± 3% for ATR (n = 212–225, p 10−15,), 470 ± 17% for Chk1 (n = 208–214, p 10−15,) 
and 378 ± 14% for Chk2 (n = 200–222, p 10−15,). The nuclear signal for Tau in the presence of Etoposide reached 
132 ± 2% (n = 857–859, p 10−15,) that obtained for control conditions, confirming that the DNA damage caused 
translocation of Tau to the nuclear compartment (Fig. 7c). Vinblastine caused the collapse of the microtubule 
network as shown by the presence of brightly fluorescent microtubule fragments in the perinuclear region visu-
alized with a β-tubulin antibody (Fig. 7a) but did not induce nuclear Tau translocation (Supplementary Fig. 10).
In order to evaluate a possible effect of the drug treatments, Tau phosphorylation was analysed by western blot 
in total cell lysates as well as in cytosolic and nuclear fractions (Fig. 7d). When compared to the control condi-
tions, Etoposide treatment reduced pT181 in total lysates to 42 ± 18% (mean ± SD, n = 6, p 0.01, non-parametric 
Figure 6. Subcellular fractionation reveals location-specific Tau modification. (a) Cell lysates, cytosolic and 
nuclear fractions obtained from biological triplicates of C17.2 cells induced for human Tau expression for 
24 hr are analysed by western blot with antibodies for Tau (Tau13), for the cytosolic GAPDH marker and for 
the nuclear histone 3 (H3) marker. Molecular weight markers are shown on the left. Full blots are presented 
in Supplementary Fig. 4 online. (b) Quantification is plotted as mean percent ± SD recovered in the two 
subcellular fractions. (c) Cytosolic and TCA-precipated nuclear fractions are analysed by western blot with 
antibodies for pan-Tau, against the indicated phosphosites or for dephosphorylated Ser195/198/199/202 (biological 
triplicates). (d) Quantification of modified Tau normalized for the amount of total Tau detected in each sample. 
To facilitate the comparison between sites, each modified site is further normalized with the respective values 
measured in the cytosolic fraction. Values are mean ± SD, n = 3. 2way ANOVA and Bonferroni’s multiple 
comparison test, *p < 0.05, ***p < 0.001.
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Kruskal-Wallis test), in the cytosol to 46 ± 18% (p 0.005) and, notably, even more in the nucleus to 28 ± 14% 
(p 0.001). An increase of the de-phosphorylated dependent Tau1 epitope to 155 ± 26% (p 0.024) was found in 
the nuclear fraction, but no significant changes were observed in the cytosolic fraction or in total cell lysates. 
Etoposide treatment did not affect significantly pS404. In contrast, Vinblastine-treated cells displayed reduced 
pS404 to 64 ± 9% (p 0.046, n = 3) in the cytosol and substantially also in total lysates (70 ± 7%, not significant) but 
not in the nuclear fraction (102 ± 21%). On the other hand, we found increased Tau1 signal in the presence of 
Vinblastine in total cell lysates to 211 ± 51% (p 0.019, n = 3) and in the nuclear fraction to 182 ± 31% (p 0.024) 
but this did not reach significance in the cytosolic fraction (174 ± 18%). We also tested the effect of the nuclear 
export inhibitor Leptomycin b and found a significant increase in the nuclear staining for Tau reaching 144 ± 4% 
(mean ± sem, n = 154–178 nuclei, p 10−15) but this effect on the retention of Tau in the nucleus did not affect any 
of the phosphosites of Tau analysed in the nuclear fraction, in the cytosolic fraction or in total cell lysates.
In summary, our data show that the phosphorylation of Tau differs depending on its subcellular location and 
that phosphorylation of nuclear and cytosolic Tau is regulated by different cellular pathways.
Figure 7. DNA damage induces de-phosphorylation of nuclear Tau. (a) The effect of Etoposide and Vinblastine 
treatment on mouse C17.2 cells is shown by confocal microscopy upon immune staining of PFA-fixed cells 
with antibodies against the microtubule marker β-tubulin (in cyan) or the DNA damage marker γH2A-X 
(in red). (b) Confocal microscopic quantification of the activated kinases in the nucleus (DAPI mask). Mean 
percent ± sem relative to the respective controls. 2-tailed unpaired Mann-Whitney test, ****p < 0.0001. (c) 
Confocal microscopy images of C17.2 cells with induced Tau441 expression treated in the absence or presence 
of 60 µM Etoposide for 5 hr and stained for with the human Tau antibody (Tau13). Quantification of immune 
fluorescent detection of human Tau in DAPI-stained nuclei. Mean percent ± sem relative to the control. 2-tailed 
unpaired Mann-Whitney test, ****p < 0.0001. (d) Cytosolic and nuclear fractions obtained from biological 
replicates of C17.2 cells with induced Tau expression and treated as indicated are analysed by western blot with 
antibodies for the two phosphosites pT181 and pS404 and for the dephosphorylated Tau1 epitope are quantified 
upon normalization for total Tau. Data represent mean percent ± SD relative to the untreated controls. Non-
parametric Kruskal-Wallis test, *p < 0.05, **p < 0.01.
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Discussion
With a set of cellular models and analytical methods, we investigated nuclear Tau modification and obtained 
evidence for different phosphorylation at defined sites in this cellular compartment. First evidence of subcellular 
location-dependent modification was produced by mass spectrometry of S11-Tau isolated with GFP1–10 sensors 
targeted to distinct cellular compartments. In this analysis, phosphorylation of nuclear sensor-bound Tau, when 
compared to Tau captured with the untargeted sensor, was increased at five out of thirteen Tau phosphopeptides 
detected by mass spectrometry, namely those including T181, S198/199/202, T212, S404 and the double phosphorylated 
T231/S235. Reinforcing these data, these residues, with the exception of S404, were also more phosphorylated for the 
nuclear sensor when compared to Tau isolated by means of the sensor targeted to the outer mitochondrial mem-
brane. On the other hand, association to mitochondria reduced pT231/pS235 but increased pS356, confirming the 
possibility of a mitochondria-localized pool of Tau with unique functions18. Previously published work claimed 
reduced nuclear Tau phosphorylation by immune staining with the dephosphorylated Ser195/198/199/202-specific 
antibody Tau137. Data from our laboratory indicate that the analysis of (de)phosphorylation of endogenous Tau 
by immune staining of cultured cells needs confirmation with a proper negative control. In fact, using Tau1 and 
some phospho-Tau antibodies used in this study on human SH-SY5Y cells, wild-type or with destroyed MAPT 
gene, resulted in a nucleus-localized staining that was not dependent on the presence or the absence of endoge-
nous or overexpressed Tau. Nevertheless, because of this and the fact that a second mass spectrometric analysis 
showed increased nuclear Tau phosphorylation only at residues T181 and T231/S235, we continued our study with 
two different cellular systems. First, we studied the effect of forced nuclear targeting of Tau (nucTau) by western 
blot with phospho-specific antibodies. Quantifiable signals were obtained for pT181, pT212, pS404 and for Tau1 both 
in transfected mouse C17.2 and human SH-SY5Y cells. For both cell lines, increased immune detection at the 
same four epitopes was found for nucTau. Since the utilization of the nuclear targeted sensor and of nucTau may 
influence normal cellular Tau distribution, we then investigated Tau modification in isolated nuclei of C17.2 cells 
expressing human wild-type Tau. This confirmed the presence of Tau in the nucleus at levels higher than those 
of the potential cytosolic contaminant GAPDH. When compared to the cytosolic fraction, also Tau present in 
the nuclear fraction displayed increased detection of three out of four epitopes analysed. Our data describe the 
phosphorylation status of nuclear Tau in proliferative pluripotent neuronal C17.2 and neuroblastoma SY5Y cells 
and this may not apply in differentiated cells such as neurons.
The presence of Tau in the nucleus was documented previously in vitro23–27 and in vivo28 where a diffuse dis-
tribution in the nucleoplasm or association to nucleoli in its dephosphorylated, Tau1 antibody-positive form was 
reported24,26,27,42. Within the nucleus, Tau interacts with RNA and DNA29–32 and appears to protect the neuron 
from age-related insults. In vitro, Tau raises the melting temperature of DNA43. Tau binds and bends DNA when 
its proline-rich and microtubule-binding domains associate to the AT-rich minor DNA groove independently of 
the nucleotide sequence33,36,44. These data suggest that Tau may shuttle between cytoplasm and nucleus, as canon-
ical heat-shock (HS) proteins do when they induce the HS response45,46. Indeed, rescue from HS-induced DNA 
damage is observed when nuclear-targeted Tau is expressed in Tau-deficient cells or mouse brain37,47. Linking 
the role of Tau in DNA metabolism with disease, cells expressing FTDP-17 mutations display more chromo-
somal defects that those expressing normal Tau48. Here, we show that treatment with the DNA damaging drug 
Etoposide also causes increased nuclear location of Tau, whereby this is accompanied by decreased phospho-
rylation at T181 and at the Tau1 epitope in the nuclear fraction, without affecting pS404. Decreased phosphoryl-
ation of Tau in the presence of Etoposide is remarkable in view of the many kinases that are activated during 
the DNA damage response. Considering the role of phosphorylation in regulating protein-protein interaction 
and the scaffold nature of Tau as protein linking different binding partner, it is tempting to consider that our 
data underlie a possible mechanism regulating different functions of Tau. In this regards de-phosphorylation 
of Tau during the DNA damage response at residue T181 and at the Tau1 epitope, i.e. within the proline-reach 
domain that has been implicated in dephosphorylated Tau-DNA association44, may offer a molecular mechanism 
for the DNA protective role of Tau. As a matter of fact, pT181 is the epitope commonly used to show increased 
phospho-Tau as a cerebrospinal fluid biomarker for an ongoing neurodegenerative process. Our data may indicate 
that a neurodegeneration-linked increase in pT181 could weaken the DNA protecting role of Tau. Interestingly, 
treatment of the cells with Vinblastine did not increased nuclear Tau localization and did not change pT181, but 
reduced phosphorylation of S404 in the cytoplasm but not in the nucleus, suggesting that the carboxy-terminal 
tail of Tau may have a predominant cytoplasmic function. Increased nuclear Tau retention in the presence of 
Leptomycin did not affect phosphorylation of Tau at the sites analysed in this study. Notably, increased nuclear 
Tau was found for the 1N4R isoform of Tau49, whereas a pathological form of Tau was shown to interfere with 
nuclear import and export50, indicating that additional mechanisms regulating nuclear Tau translocation and 
modification exist.
Tau alters the integrity of cytoplasmic and nuclear RNA47 and may regulate RNA metabolism when present 
in stress granules, which protect RNA from degradation during cellular stress51. Nuclear localization and a role 
of Tau in DNA and RNA homeostasis are reminiscent to TDP-43 and FUS, two other proteins involved in fron-
totemporal dementia (FTD)52,53. These are RNA binding proteins that play key roles in transcription, mRNA 
splicing, stability and transport. Their subcellular location is affected by autosomal dominant FTD mutations52,53. 
It is tempting to consider a common pathway for Tau/TDP/FUS-linked FTD. Whilst FUS is clearly involved in 
the DNA damage response54–56, a role of TDP-43 and Tau appears less evident. Further knowledge on nuclear Tau 
may provide clues in the understanding of FTD involving TDP-43 and FUS proteins. Due to the wide distribution 
in the CNS and periphery, Tau is potentially a global player for genome surveillance, in particular against DNA 
insults accumulating as a function of aging.
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Materials and Methods
Expression plasmids. cDNAs were inserted in the constitutive expression vector pcDNA3 or in 
pcDNA5 for inducible expression. For nucGFP1–10, the GFP1–10 plasmid38 was modified at the amino-terminus 
with a nuclear targeting sequence consisting of an artificial peptide carrying three tandem sequence derived from 
the SV40 large T antigen (MDIDPKKKRKVDPKKKRKVDPKKKRKVD)39. To insert this sequence, we used 
as template GFP1–10 for a PCR with the three overlapping forward primers TCGGATCCATGGAC 
CCGAAGAAGAAACGCAAGGTCGATCCGAAGAAG, CAAGGTCGATCCGAAGAAGAAGCGGAA 
GGTCGATCCAAAGAAAAAAAGG and CGATCCAAAGAAA AAAAGGAAGGTGTCCAAAGGAGAA 
GAACTG and the reverse primer TTCACTCGAGCTATGTTCCTTTTTCATTTGG. This inserted also 
the restriction sites BamHI and XhoI (in bold) for subcloning the amplified fragment in pcDNA3, whereby 
the initial methionine of GFP was eliminated. The signal peptide at the amino-terminus of erGFP1–10 
(MLLSVPLLLGLLGLAVA) was that of human calreticulin and was obtained with the forward p ri mer C AC-
GCAGGAATTCATGCTGCTATCCGTGCCGCTGCTGCTCGGCCTCCTCGGCCTGGCCGTCGC
CTCCAAAGGAGAAGAACTG (the initial methionine of GFP was eliminated) and the reverse primer 
ACTTCTCACTCGAGTTACAGCTCGTCCTTTGTTCCTTTTTCATTTGGATC, which also inserted a KDEL 
sequence for retention in the ER before the stop codon of GFP1–1040.
Tau expression plasmids encoded the 441 amino acid-splice variant 2N4R of human Tau. The plasmid encoding 
for untagged Tau, S11-Tau, and Tau-S11 were generated as described38. The nuclear targeting sequence of nucTau was 
the same used for nucGFP1–10 and obtained with forward primer ATATAAGCTTACCATGGATATCGACCCGAAG 
and reverse primer TTAAGGATCCATCCACCTTCCTTTTTTTCTTTGG. The amplified fragment was then 
inserted before the Tau cDNA at the restriction sites HindIII and BamHI (in bold) to obtain the desired pol-
ypeptide with the nuclear targeting sequence followed by a short linker (GST) and the sequence of human 
Tau including the initial methionine. The plasmid encoding for erTau-S11, was generated using as template 
Tau-S11, and the primers TTCGGATCCATGAAGACCATCATTGCTTTGAGCTACATTTTCTGTCT 
GGCTCTCGGCCAAGACCTTCCAGGAAATGACAACAGCACAGCAGCTGAGCCCCGCCAGG and 
TTCACTCGAGTCATGTGATGCCGGCGGCGTTC followed by subcloning with BamHI and XhoI (in bold) in 
pcDNA3. The inserted sequence corresponded to MKTIIALSYIFCLALGQDLPGNDNSTA, which covered the signal 
peptide and the amino-glycosylation consensus sequence (underlined) of influenza A hemagglutinin without the initial 
methionine of Tau.
Cell culturing, cell lines and plasmid transfections. Mouse multipotent neural progenitor C17.2 cells 
and human neuroblastoma SH-SY5Y cells were cultured as described previuosly38. Inducible C17.2 cell lines were 
generated with the Flp-In T-Rex tetracycline-inducible cell system according to the manufacturer instructions 
(Invitrogen, K650001) and were selected and maintained in the presence of 150 µg/mL Hygromycin B and 15 µg/ml 
Blasticidin S. Protein expression was induced by one day-incubation with 30 ng/mL Tetracycline, a treatment 
time and dose that were sufficient to reach steady-state levels of expression. Plasmid transfections were performed 
with Lipofectamine 3000 (Invitrogen, L-3000-008) as described38.
Drug treatments. During the last 5 h of tetracycline incubation, C17.2 cells with inducible Tau expres-
sion were treated with 60 µM Etoposide (Abcam, ab120227; 100 mM stock in DMSO), 3 µM Vinblastine 
(Sigma-Aldrich, V1377; 11 mM stock in DMSO), or 60 nM Leptomycin B (Sigma-Aldrich, L2913; 10.3 µM in 
70% ethanol). At the end of the drug treatment, cells were fixed and processed for fluorescence microscopy. For 
the immune fluorescence quantification of nuclear Tau and activated kinases, a DAPI mask on ImageJ was used.
Fluorescence microscopy. For immune fluorescence microscopy, cells were routinely grown on 8-well 
slides (Ibidi, 80826-IBI) coated with poly-D-lysine. One day after plasmid transfection, cells were fixed either 
in paraformaldehyde (PFA) or in methanol. For PFA, a 4% solution in PBS pre-warmed at 37 °C was added 1:1 
(V:V) to the culture medium for 10 min at 37 °C, followed by a second 5 min fixation in 4% PFA at room tem-
perature, 5 min quenching in 100 μM glycine and three washes with PBS. For methanol, the culture medium 
was replaced with methanol chilled at −20 °C followed by 10 min incubation at −20 °C. Then, the methanol 
solution was removed by aspiration and the fixed cell layer gently washed three times with PBS. For the immune 
staining procedure, all steps were performed at room temperature. The fixed cells were blocked with 5% normal 
goat serum, 0.3% Triton X-100 in PBS for 1 h followed by PBS washes. The antibodies were diluted in a working 
solution composed of 0.5% normal goat serum, 0.3% Triton X-100 in PBS. Primary antibodies, usually incubated 
for 1 h at 37 °C, were specific for human Tau (Tau13, Santa Cruz, sc-21796, used at 1 μg/mL), GFP (Proteintech 
Europe, 66002–1-Ig, 7 μg/mL), calnexin (kind gift of Prof. Maurizio Molinari, IRB, Bellinzona, Switzerland, 
diluted 1:1,000), α-tubulin (Abcam, ab1825, 0.5 μg/mL or Cell Signaling, DM1A, diluted 1:500), pS129-H2A.X 
(Santa Cruz, sc-517348, 0.5 μg/mL), pATM (Cell Signaling, S1981, diluted 1:500), pChk1 (Cell Signaling, S345, 
diluted 1:500), pChk2 (Cell Signaling, T68, diluted 1:500), pATR (Cell Signaling, S428, diluted 1:500). Secondary 
antibodies (2 μg/mL for 1 h at room temperature in the dark) were anti-mouse IgG (Thermo Fisher Scientific, 
Alexa594, A-11032, or Alexa 488, A-11001) or anti-rabbit IgG (Thermo Fisher Scientific, Alexa594, A-11037, 
or Alexa488 A-11034). Nuclei were counterstained with DAPI (0.5 μg/mL). After the staining, cells were kept in 
0.05% sodium azide in PBS in the fridge before analysis with a confocal microscope (Nikon C2). Images were 
taken with a line by line scan using a sequence of excitation with the 405 nm laser and emission filter 464/40–
700/100 nm, 488 nm laser and emission filter 525/50 nm, and 561 nm laser and 561/LP nm emission filter.
Cell lysis and western blotting. Cells were rinsed once with PBS and collected by scraping and low 
speed centrifugation. Cell lysates were prepared in 100 μL ice-cold RIPA supplemented with inhibitor cocktails 
for proteases (Sigma-Aldrich, S8820) and phosphatases (Sigma-Aldrich, 04906845001). All samples were then 
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maintained on ice or at 4 °C. Cell lysates were shaken for 30 min at 1,400 rpm (Eppendorf, Thermomixer 5355) 
and RIPA extracts collected after centrifugation for 10 min at 20,000 g. Total protein concentration was deter-
mined by Bradford (Pierce, BCA Protein Assay Kit 23227). For phosphatase treatment, RIPA extracts (10 μg 
protein), prepared without phosphatase inhibitors, were incubated in the absence or presence of 20 U/μL Lambda 
PP (BioLabs, P0753S) for 1 h at 30 °C as described by the supplier. Total cell lysates were prepared by direct 
solubilisation of cell pellets in 100 μL sample buffer: 1.5% SDS, 8.3% glycerol, 0.005% Bromophenol blue, 1.6% 
β-mercaptoethanol and 62.5 mM Tris-HCl pH 6.8.
SDS-polyacrylamide gel electrophoresis was performed on hand-casted 10% gels at constant 90–110 V 
(Bio-Rad, Mini-PROTEAN 1658033FC). Protein was transferred on PVDF membranes (Merck-Millipore, 
Immobilon-FL IPFL00010) using a Trans-Blot Turbo Transfer System (Bio-Rad, 1704150). After the transfer, 
the membranes were incubated in blocking buffer (Licor Biosciences Odyssey, 927–50000) for 1 h at room tem-
perature. Bound primary antibodies were revealed by the two secondary antibodies anti-mouse IgG coupled to 
IRDye RD 680 or anti-rabbit IgG coupled to IRDye 800CW (Licor Biosciences, 926–68070 and 926–32211) on a 
dual infrared imaging scanner (Licor Biosciences, Odyssey CLx 9140) and quantified with the software provided 
(Licor Biosciences, Image Studio V5.0.21, 9140–500). Antibodies used for western blot were Tau13 (0.2 μg/mL), 
Tau1 (Merck-Millipore, MAB-3420, 0.5 μg/mL), phospho-Tau T181 (AT270, Invitrogen, MN1050, 0.2 μg/mL), T212 
(Abcam, ab4842, 1:1,000), S404 (Invitrogen, 44–758 G, 1:1,000), GAPDH (Abcam, ab181602, 1:2,500), histone 3 
(Abcam, ab176842, 1:10,000), β-actin (Sigma-Aldrich, A1978, 0.084 μg/mL), and GFP (Abcam, ab5449, 1:5,000).
Samples preparation for LC-MS/MS. Detergent-free extracts were prepared in PBS supplemented with 
protease and phosphatase inhibitors by three freeze/thaw cycles in liquid nitrogen followed by centrifugation 
for 10 min at 20,000 g. Immune isolation of complemented GFP was performed on magnetic beads. For this, cell 
extracts obtained by pooling biological triplicate (at least 600 μg total protein) were brought to 500 μL with PBS, 
supplemented with 5 μL of 50% magnetic bead slurry GFP-Trap (ChromoTek, gtma-20) and incubated on an 
orbital rotator (Labnet, 096621) for 2 h at 4 °C. With the aid of a magnet, the beads were washed twice with PBS 
and once with water. A small portion of the beads was eluted with sample buffer to analyse the immune isolates 
by western blot.
Proteolytic peptides were obtained by double digestion. For this, GFP-trap bead-bound immune isolates were 
resuspended in 50 µL 50 mM NH4HCO3 and 8 M urea and reduced in 2 µM dithiotreitol for 1 h at 37 °C with shak-
ing at 800 rpm. Proteins were then alkylated in 4.5 mM iodoacetamide for 45 min in the dark at room tempera-
ture. Sequential digestion was performed for 3 h with Lys-C (WAKO, 125–05061; 20 ng/µL), and then overnight 
with trypsin (Promega, V5113; 2.5 ng/µL) by adding 144 µL 50 mM NH4HCO3. The digestion was stopped by 
acidification to pH < 3 with 50% formic acid. The peptide mixtures were loaded on C18 spin tips (Pierce, 84850), 
and desalted twice with 0.1% formic acid by centrifugation for 1 min at 100 g. Peptides were eluted twice with 80% 
acetonitrile, lyophilized (Eppendorf, Concentrator plus 5305), solubilized in 0.1% formic acid and analysed by 
mass spectrometry.
LC-MS/MS. Samples were measured on a nanoLC (Thermo Fisher, EASY-nLC 1000) coupled to a mass 
spectrometer (Thermo Fisher, Q Exactive Plus). Peptides were separated on a 40 cm × 0.75 μm column packed 
in-house with reversed-phase resin (ReproSil-Pur C18- AQ 1.9 μm, Dr. Maisch). Peptides were eluted for 60 min 
using a segmented linear 5–40% gradient (solvent A: 0.1% formic acid; solvent B: 99.9% acetonitrile, 0.1% formic 
acid) at 300 nL/min. Survey full-scan mass spectra were acquired with mass range 350–1,500 m/z, at a resolution 
of 70,000 at 200 m/z and the 20 most intense ions above an intensity of 3.6e4 were sequentially isolated, frag-
mented (HCD at 25 NCE) and measured at a resolution of 17,500 at 200 m/z. Peptides with a charge of + 1 or with 
unassigned charge state were excluded from fragmentation for MS2, and a dynamic exclusion of 30 s was applied. 
Ions were accumulated to a target value of 3e6 for MS1 and of 1e5 for MS2.
In Sequest HT, mass spectra were searched against a mouse database (Uniprot, downloaded July 8th, 2016; 
supplemented with sequences of human Tau). Carbamidomethylation of cysteine was set as a fixed modification 
and oxidation of methionine and phosphorylation of serine, threonine and tyrosine were allowed as a variable 
modification. Precursor mass tolerance was 10 ppm and fragment mass tolerance 0.02 Da. Trypsin was set as 
enzyme allowing for maximally two missed cleavages. Percolator was used to filter the results to 1% FDR at 
peptide level and phosphoRS 3.0 for phosphorylation-site localization. Skyline 3 was used to extract the monoi-
sotopic and the first and second isotope precursor intensity traces of all identified Tau peptides.
Cytosolic and nuclear fractionation. The protocol was derived from an online method (Abcam). All 
samples were maintained on ice and all centrifugations were performed at 4 °C. C17.2 cells were washed once with 
PBS and scraped in hypotonic buffer: 250 mM sucrose, 10 mM KCl, 2 mM CaCl2, 1.5 mM MgCl2, 20 mM HEPES 
pH 7.4, supplemented with protease and phosphatase inhibitors. Cells were broken by passing the cell suspension 
four times through a 25-gauge needle. An aliquot of this sample was collected and labelled as “total”. The cytosolic 
fraction was obtained as supernatant of a sequential centrifugation for 5 min at 1,000 g and for 10 min at 20,000 g. 
For the nuclear fraction, the pellet from the first centrifugation was washed twice by sequential resuspension in 
hypotonic buffer, ten-time passage through a 25-gauge needle and centrifugation for 10 min at 1,000 g. The final 
pellet was resuspended in RIPA supplemented with 1.25 mM MgCl2, protease and phosphatase inhibitor, treated 
with Benzonase nuclease (Merck-Millipore, 70746–4, 0.56 U/µL) for 15 min at 37 °C and collected as the super-
natant of a final centrifugation for 10 min at 20,000 g.
In order to concentrate the nuclear fraction, this was mixed with 1 volume of 20% TCA, incubated for 30 min 
on ice and centrifuged 20 min at 20,000 g. The pellet was washed with −20 °C cold 100% acetone, followed by 
centrifugation for 20 min at 20,000 g. After supernatant removal, residual acetone was evaporated at room tem-
perature and the samples resuspended in SDS PAGE sample buffer and neutralization with 1 M Tris-HCl pH 10.8
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Statistical analysis. Statistical analysis was performed with the aid of GraphPad Prism version 7.02 as indi-
cated in the results section and figure legends.
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